BIOMAT Database Logo BIOMAT Database Logo

Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and tumor-infiltrating lymphocytes activated by PSK. 1991

Y Kariya, and N Okamoto, and T Fujimoto, and N Inoue, and T Kihara, and K Sugie, and M Yagita, and H Kanzaki, and T Mori, and A Uchida
Department of Late Effect Studies, Kyoto University.

The protein-bound polysaccharide PSK was tested for the ability to induce in vitro autologous tumor killing (ATK) activity in human cancer patients. Peripheral blood lymphocytes (PBL) and tumor-infiltrating lymphocytes (TIL) demonstrated various levels of cytotoxicity against autologous, freshly isolated tumor cells. When PBL and TIL were cultured overnight with PSK, ATK activity was induced in previously non-reactive cases and augmented in previously reactive samples. The PSK effect was observed with PSK concentrations of 10-100 micrograms/ml that could be obtained in the blood of cancer patients who received standard oral administration of PSK. The manifestation of PSK-induced ATK required active cell metabolism and RNA and protein syntheses, but not DNA synthesis of lymphocytes. PSK-induced enhancement of ATK was not abrogated by monoclonal antibodies (mAb) directed against interferon (IFN) alpha or IFN gamma. In addition, mAb that neutralized interleukin-2 (IL-2) or mAb reactive with alpha-chain or beta-chain of IL-2 receptors (IL-2R) had no effect on PSK-induced ATK activity. Supernatants from PSK-stimulated lymphocyte cultures did not induce ATK. Cell fractionation experiments revealed that CD3-CD16+ large granular lymphocytes (LGL) and/or CD3+CD16- T lymphocytes were responsible for both spontaneous and PSK-induced ATK. PSK-activated LGL, but not T lymphocytes expressed lysis of fresh allogeneic tumor cells. These results indicate that PSK activates PBL and TIL to exhibit ATK independently of IL-2/IL-2R systems.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011509 Proteoglycans Glycoproteins which have a very high polysaccharide content. Proteoglycan,Proteoglycan Type H

Related Publications

Y Kariya, and N Okamoto, and T Fujimoto, and N Inoue, and T Kihara, and K Sugie, and M Yagita, and H Kanzaki, and T Mori, and A Uchida
Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK432.
October 1983, Journal of the National Cancer Institute,
Y Kariya, and N Okamoto, and T Fujimoto, and N Inoue, and T Kihara, and K Sugie, and M Yagita, and H Kanzaki, and T Mori, and A Uchida
Lysis of fresh human tumor cells by autologous large granular lymphocytes from peripheral blood and pleural effusions.
July 1983, International journal of cancer,
Y Kariya, and N Okamoto, and T Fujimoto, and N Inoue, and T Kihara, and K Sugie, and M Yagita, and H Kanzaki, and T Mori, and A Uchida
Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization.
January 1983, Cancer immunology, immunotherapy : CII,
Y Kariya, and N Okamoto, and T Fujimoto, and N Inoue, and T Kihara, and K Sugie, and M Yagita, and H Kanzaki, and T Mori, and A Uchida
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
June 1982, The Journal of experimental medicine,
Y Kariya, and N Okamoto, and T Fujimoto, and N Inoue, and T Kihara, and K Sugie, and M Yagita, and H Kanzaki, and T Mori, and A Uchida
Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes.
January 1987, Cancer research,
Y Kariya, and N Okamoto, and T Fujimoto, and N Inoue, and T Kihara, and K Sugie, and M Yagita, and H Kanzaki, and T Mori, and A Uchida
Enhanced susceptibility of adriamycin-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes and tumor infiltrating lymphocytes.
August 2007, Oncology reports,
Y Kariya, and N Okamoto, and T Fujimoto, and N Inoue, and T Kihara, and K Sugie, and M Yagita, and H Kanzaki, and T Mori, and A Uchida
Lysis of autologous human melanoma cells by in vitro allosensitized peripheral blood lymphocytes.
January 1982, Cancer immunology, immunotherapy : CII,
Y Kariya, and N Okamoto, and T Fujimoto, and N Inoue, and T Kihara, and K Sugie, and M Yagita, and H Kanzaki, and T Mori, and A Uchida
Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells.
January 1989, Cancer immunology, immunotherapy : CII,
Y Kariya, and N Okamoto, and T Fujimoto, and N Inoue, and T Kihara, and K Sugie, and M Yagita, and H Kanzaki, and T Mori, and A Uchida
Potential therapeutic use of autologous human lymphocytes in metastatic melanoma: in vivo interleukin 2-activated peripheral blood lymphocytes and in vitro activated peripheral blood and tumor-infiltrating lymphocytes.
January 1988, Advances in experimental medicine and biology,
Y Kariya, and N Okamoto, and T Fujimoto, and N Inoue, and T Kihara, and K Sugie, and M Yagita, and H Kanzaki, and T Mori, and A Uchida
Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response.
July 1991, Journal of the National Cancer Institute,
Copied contents to your clipboard!